On Tuberculosis and COVID-19 co-infection

Marina Tadolini, José-María García-García, François-Xavier Blanc, Sergey Borisov, Delia Goletti, Ilaria Motta, Luigi Ruffo Codecasa, Simon Tiberi, Giovanni Sotgiu, Giovanni Battista Migliori


This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
On Tuberculosis and COVID-19 co-infection

Marina Tadolini¹, José-María Garcíá-Garcíá², François-Xavier Blanc³, Sergey Borisov⁴, Delia Goletti⁵, Ilaria Motta⁶, Luigi Ruffo Codecasa⁷, Simon Tiberi⁸,⁹, Giovanni Sotgiu¹⁰, Giovanni Battista Migliori¹¹ on behalf of the GTN TB/COVID group*

1. Unit of Infectious Diseases, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy
2. Tuberculosis Research Programme (PII-TB), SEPAR, Barcelona, Spain
3. Centre Hospitalier Universitaire, Nantes, France
4. Moscow Research and Clinical Center for TB Control, Moscow, Russian Federation
5. Translational Research Unit, National Institute for Infectious Diseases ‘L. Spallanzani’, IRCCS, Rome, Italy
6. Dipartimento di Scienze Mediche, Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy
7. TB Reference Centre, Villa Marelli Institute, Niguarda Hospital, Milan, Italy
8. Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
9. Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
10. Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
11. Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy

Address for correspondence: Giovanni Battista Migliori, Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Via Roncaccio 16, Tradate, Varese, 21049, Italy. E-mail: giovannibattista.migliori@icsmaugeri.it

Take home message: COVID-19 may boost tuberculosis given infection and mortality, further studies are needed

Key words: TB, COVID-19, mortality, quality of life, rehabilitation

Text 572 words
Dear Editor,

we wish to thank, Alkesh Khurana and Deepak Aggarwal [1] for their interest in our research letter and comments [1].

In their correspondence, the Authors raised two important issues, namely the possible association between tuberculosis (TB) and COVID-19 (can infection by SARS-CoV-2 reactivate TB?) and the effects of TB on early mortality in co-infected patients.

Our research letter reported the first cohort of patients with diagnosis of TB (including post-treatment sequelae) and COVID-19. The article was aimed at reporting what was observed at the beginning of the epidemic among some of the most affected countries. This explains the small numbers described and the countries involved. At the time the article was submitted several countries in Africa, Europe and Latin America represented in the Global Tuberculosis Network (GTN) had no TB/COVID-19 patients to report.

In the absence of previous cohorts and scientific information on the TB/COVID-19 co-infection, we have described the timing of diagnosis of the two diseases, observing that one third had COVID-19 diagnosed prior to TB and 18% were diagnosed simultaneously.

We agree, it is possible that the diagnosis of COVID was made before TB because of acute onset of symptoms caused by SARS-CoV2 in addition to the alarm generated by the COVID-19 pandemic, which determined rapid access to radiological examinations and subsequent discovery of underlying tuberculosis. In fact we commented this in point 3 of our article [2], and we abstained from making any clear statement about causal association. However, we could not exclude that the infection by SARS-CoV-2 or the drugs utilized might have accelerated the progression of a pre-existing TB infection to disease.

However, apart from the speculation on what disease comes first, it is evident that the co-existence of TB and COVID-19 poses a challenge in differential diagnosis [2].

The study was observational, and based on a relatively small cohort, and therefore we fully agree that larger prospective studies are necessary to shed further light on this to establish whether there is an association or not.

The Authors [1] also raised the important question whether TB has a real effect or ‘weight’ in increasing the probability of death in COVID-19 patients.
The issue has been described in a second article [3] which reports the findings of 69 patients from our original cohort plus a second cohort [4] which was managed in a reference hospital in Northern Italy.

The patients likelier to die were those of older age with pre-existing co-morbidities [3].

It is important to emphasise that the cohort of young migrants without co-morbidities reported elsewhere [3,4] experienced a milder form of COVID-19 with no deaths.

However, in countries where risk factors for mortality are highly prevalent among young individuals (smoking, alcohol and substance abuse, HIV co-infection, among others), particularly in the presence of drug-resistance and difficult access to diagnosis (delayed diagnosis), the impact of mortality may be higher. We agree that in resource-limited settings poverty and malnutrition might play an important role in increasing morbidity and mortality.

Furthermore, we do agree that the population of individuals with post-TB treatment sequelae deserves further evaluation, given the potential effect of both TB and COVID-19 on quality of life and subsequent need for rehabilitation [5-7].

In order to better understand the implication of TB and COVID-19 co-infection the study is continuing: more countries and a larger sample size will help answering some of the questions left open by our original study [2]. We will be happy to collaborate with all interested colleagues.

Acknowledgements

The article is part of the scientific activities of the Global Tuberculosis Network (GTN); GREPI (Groupe de Recherche et d'Enseignement en Pneumo-Infectiologie), a working group from SPLF (Société de Pneumologie de Langue Française); SEPAR (Sociedad Española de Neumología and Cirugía Torácica); Moscow Society of Phtisiology and of the WHO Collaborating Centre for Tuberculosis and Lung Diseases, Tradate, ITA-80, 2017-2020-GBM/RC/LDA).

*The members of the GTN TB/COVID group are:
Jan-Willem Alffenaar (Australia); Pierre Bachez (Belgium); Denise Rossato Silva (Brazil); Claire Andréjak, François-Xavier Blanc, Samir Dourmane, Mathilde Fréchet Jachym, Antoine Froissart, Soazic Grard, Armine Izadifar, Damien Le Du, Frédéric Rivière and Frédéric Schlemmer (France); Rosella Centis, Luigi Ruffo Codecasa, Lia D’Ambrosio, Vania
Giacomet, Delia Goletti, Gina Gualano, Filippo Lipani, Giovanni Battista Migliori, Ilaria Motta, Maria Musso, Fabrizio Palmieri, Emanuele Pontali, Matteo Saporiti, Paolo Scarpellini, Giovanni Sotgiu, Antonio Spavuvello, Claudia Stochino, Marina Tadolini, Alessandro Torres, Simone Villa and Dina Visca (Italy); Evgeny Bililovski, Sergey Borisov and Elena Sumarokova (Russian Federation); Paul Anantharajah Tambyah and Catherine Wei Min Ong (Singapore); José Cardoso-Landivar, María-Luiza De Souza-Galvão, Angel Domínguez-Castellano, José-María García-García, Margarita Marín Royo, Teresa Rodrigo, Adrián Sánchez-Montalvá, Eva Tabenero and Miguel Zabaleta Murguiondo (Spain); Pierre-Alexandre Bart and Jesica Mazza-Stalder (Switzerland); Simon Tiberi (United Kingdom)
References


